Definium Therapeutics (DFTX) Non Operating Investment Income (2025 - 2026)
Definium Therapeutics (DFTX) posted quarterly Non Operating Investment Income of -$262000.0 for Q1 2026, down 2720.0% year-over-year from $10000.0 in Q1 2025, and down 397.73% quarter-over-quarter from $88000.0 in Q4 2025.
Powered by 
Analysis
Definium Therapeutics (DFTX) Non Operating Investment Income (2025 - 2026) Analysis & Trends
Definium Therapeutics (DFTX) has reported Non Operating Investment Income for 2 consecutive years, with -$262000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Non Operating Investment Income fell 2720.0% year-over-year to -$262000.0; the TTM figure through Mar 2026 stood at $58000.0 (changed N/A YoY), while the FY2025 annual figure was $330000.0, changed N/A from the prior year.
- Non Operating Investment Income retreated to -$262000.0 in Q1 2026 per DFTX's latest filing, from $88000.0 in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $196000.0 in Q3 2025 and bottomed at -$262000.0 in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Definium Therapeutics | 4.23 Bn | 4.23 Bn | - | -406,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -406,000.00 |
| Mar 31, 2026 | -262,000.00 |
| Dec 31, 2025 | 88,000.00 |
| Sep 30, 2025 | 196,000.00 |
| Jun 30, 2025 | 36,000.00 |
| Mar 31, 2025 | 10,000.00 |